Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 8 July 2025, 08:31 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

TOKYO, July 8, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it has been selected for the highest rating of “Supplier Engagement Leader” in the Supplier Engagement Rating by the global environmental non-profit organization CDP.(1)

The Supplier Engagement Assessment evaluates how effectively companies are working with suppliers to address climate change issues. In its responses to the CDP Climate Change Questionnaire on 'Governance', 'Targets', 'Scope 3 emissions(2)' and 'Value chain engagement', Eisai’s efforts to engage with suppliers were highly regarded, leading to this selection. To conduct environmentally conscious business activities throughout our entire supply chain, Eisai asks business partners to comply with the “Eisai Global Code of Conduct for Business Partners(3)” which clearly states Eisai’s requirement for environmental conservation. Collaboration with suppliers is also strengthened by conducting sustainability assessments of partners and providing feedback on the results.

Eisai identifies “Business activities with consideration for the global environment” as one of its material issues. Based on the “Eisai Network Companies Environmental Protection Policy”, Eisai is promoting responses to climate change as key environmental activities across the group. Eisai is working towards the realization of a decarbonized society, including receiving approval for the SBT 1.5°C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI)Race to Zero Circle, which calls for achieving net zero by 2050.(4)

Please refer to Eisai’s website for more detailed information about its environmental activities.

The preservation of the global environment is essential for realizing Eisai’s corporate concept of human health care (hhc). Eisai will contribute to empowering people to “realize their fullest lives” through our climate change initiatives.

(1)A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system.
(2)Indirect greenhouse gas emissions across the entire corporate value chain
(3)Please refer here for further details
(4)Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GASREDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050
https:/www.eisai.com/news/2024/news202412.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

 




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 3, 2025 17:19 HKT/SGT
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 2, 2025 23:01 HKT/SGT
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Nov 28, 2025 22:00 HKT/SGT
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 26, 2025 18:42 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 17, 2025 21:08 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Oct 30, 2025 13:43 HKT/SGT
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 28, 2025 23:30 HKT/SGT
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: